Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
Date:4/29/2008

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that the following clinical and preclinical abstracts for ipilimumab in melanoma, prostate cancer and other cancers, as well as for anti-PD-1 and anti-CD70 antibody candidates for cancer treatment, are expected to be the subject of presentations at the Annual Meeting of the American Society of Clinical Oncology, being held May 30-June 3, 2008 in Chicago:

Survival, Response, Safety and Biomarker Data of Ipilimumab in Melanoma

-- "Antitumor response and new lesions in advanced melanoma patients on

ipilimumab treatment" (Abstract #3020, Developmental Therapeutics:

Immunotherapy Session) -- Poster presentation and discussion from 2:00

p.m. to 6:00 p.m. local time on Friday, May 30, 2008.

-- "Long-term survival of patients with advanced melanoma who received

ipilimumab administered at 10mg/kg every 3 weeks for 4 doses (induction

dosing)" (Abstract #3018, Developmental Therapeutics: Immunotherapy

Session) - Poster presentation and discussion from 2:00 p.m. to 6:00

p.m. local time on Friday, May 30, 2008.

-- "Potential immune biomarkers of gastrointestinal toxicities and

efficacy in patients with advanced melanoma treated with ipilimumab

with or without prophylactic budesonide" (Abstract #3022, Developmental

Therapeutics: Immunotherapy Session) -- Poster presentation and

discussion from 2:00 p.m. to 6:00 p.m. local time on Friday, May 30,

2008.

-- "Novel efficacy criteria for antitumor activity to immunotherapy using

the example of ipilimumab, an anti-CTLA-4 monoclonal antibody"

(Abstract #3008, Developmental Therapeutics: Immunotherapy

Session) -- Oral presentation beginning at 4:30 p.m. local time one

Saturday, May 31, 2008.

-- "Effect of prior treatment status on the efficacy and safety of

ipilimumab monotherapy in treatment-naive and previously treated

patients with advanced melanoma" (Abstract #9055, Melanoma

Session) -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time

on Saturday, May 31, 2008.

-- "An analysis of the effectiveness of specific guidelines for the

management of ipilimumab-mediated diarrhea/colitis: prevention of

gastrointestinal perforation and/or colectomy" (Abstract #9063,

Melanoma Session) - Poster presentation from 2:00 p.m. to 6:00 p.m.

local time on Saturday, May 31, 2008.

-- "Model-based evaluation of ipilimumab dosage regimen in patients with

advanced melanoma" (Abstract #9073, Melanoma Session) -- Poster

presentation from 2:00 p.m. to 6:00 p.m. local time on Saturday, May

31, 2008.

-- "Safety and efficacy of ipilimumab with or without prophylactic

budesonide in treatment-naive and previously treated patients with

advanced melanoma" (Abstract #9010, Melanoma Session) -- Oral

presentation beginning at 10:15 a.m. local time on Sunday, June 1,

2008.

-- "Efficacy and safety of ipilimumab induction and maintenance dosing in

patients with advanced melanoma who progressed on one or more prior

therapies" (Abstract #9021, Melanoma Session) -- Poster presentation

and discussion from 2:00 p.m. to 6:00 p.m. local time on Sunday, June

1, 2008.

-- "Disease control and long-term survival in chemotherapy-naive patients

with advanced melanoma treated with ipilimumab (MDX-010) with or

without dacarbazine" (Abstract #9022, Melanoma Session) -- Poster

presentation and discussion from 2:00 p.m. to 6:00 p.m. local time on

Sunday, June 1, 2008.

-- "Dose effect of ipilimumab in patients with advanced melanoma: results

from a phase 2, randomized, dose-ranging study" (Abstract #9025,

Melanoma Session) -- Poster presentation and discussion from 2:00 p.m.

to 6:00 p.m. local time on Sunday, June 1, 2008.

-- "Prolonged survival in objective responders to ipilimumab therapy"

(Abstract #20004) -- Publication only.

Response and Safety Data of Ipilimumab in Prostate

-- "Phase 1 trial of ipilimumab (IPI) alone and in combination with

radiotherapy (XRT) in patients with metastatic castration resistant

prostate cancer (mCRPC)" (Abstract #5004, New Targeted Strategies for

Patients with Prostate Cancer Session) -- Oral presentation beginning

at 11:30 a.m. local time on Monday, June 2, 2008.

-- "Expanded phase 1 combination trial of GVAX immunotherapy for prostate

cancer and ipilimumab in patients with metastatic hormone-refractory

prostate cancer (mHRPC)" (Abstract #5146, Genitourinary Cancer Session)

-- Poster presentation from 8:00 a.m. to 12:00 p.m. local time on

Saturday, May 31, 2008.

Clinical and Preclinical Data of Additional Immunotherapy and Antibody-Drug Conjugate Programs

-- "Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal

antibody, in patients with selected refractory or relapse malignancies"

(Abstract #3006, Developmental Therapeutics: Immunotherapy

Session) -- Oral presentation beginning at 4:00 p.m. local time on

Saturday, May 31, 2008.

-- "Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in

combination with ixabepilone in preclinical tumor models" (Abstract

#3048, Developmental Therapeutics: Immunotherapy Session) -- Poster

presentation from 2:00 p.m. to 6:00 p.m. local time on Sunday, June 1,

2008.

-- "Effect of a fully human anti-CD70 antibody on apoptosis and

dephosphorylation of MAPK proteins in chronic lymphocytic leukemia"

(Abstract #3073, Developmental Therapeutics: Immunotherapy

Session) -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time

on Sunday, June 1, 2008.

More information about the ASCO Annual Meeting may be found at http://www.asco.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
2. Medarex Announces Ipilimumab Program Continues to Move Forward
3. Medarex to Receive Milestone Payment from Amgen
4. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
7. XTENT Announces First Quarter 2008 Financial Results
8. Neuralstem Announces Issuance of Core Technology Patent in Europe
9. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
10. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 Prima BioMed ... TACTI-mel trial of IMP321 in combination with Keytruda, with ... (1mg/kg) cohort experiencing a complete response. Recruitment in the ... expected to be fully recruited by Q317. Preliminary efficacy ... breast cancer study are expected mid-year (recruitment in the ...
(Date:3/23/2017)... ALBANY, New York , March 23, 2017 ... devices market exhibits a consolidated vendor landscape with the ... the overall market in 2015. These companies are ... Industries, Inc., Hygia Health Services, Inc., and VANGUARD ... global reprocessed medical devices market is witnessing the ...
(Date:3/23/2017)... , March 23, 2017 ... Enterprises Limited, anuncia el nombramiento de Stuart ... una plataforma de servicios integrados completa para su ... un cargo clave en el crecimiento y ejecución ... será responsable de impulsar todas las actividades de ...
Breaking Medicine Technology:
(Date:3/23/2017)... Holland, PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI ... the modular industry or whose acts have had a significant impact on the careers of ... Sales and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Management Accreditation from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, ... status is granted to organizations that have excellent programs for the delivery and ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Sharon Kleyne, host of the ... and Your Health on VoiceAmerica, recently talked on her program about how she is ... occasion to remind listeners of an important distinction. World Water Day, Kleyne pointed out, ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... products at competitive pricing. Verisys through its FACIS and other ... restrictions and Disciplinary actions. , “We are delighted to be able to offer ...
Breaking Medicine News(10 mins):